Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Pain is a recognized association with LGI1-/ CASPR2-antibodies. Of 147 patients, pain was experienced by 17/33 (52%) CASPR2- versus 20/108 (19%) LGI1-antibody patients (p=0.0005), and identified as neuropathic in 89% versus 58% of these, respectively. Typically, normal nerve conduction studies and reduced intraepidermal nerve fibre densities were observed in subsets of both cohorts. In LGI1-antibody patients, pain responded to immunotherapy (p=0.008), often rapidly, with greater residual patient-rated impairment observed in CASPR2-antibody patients (p=0.019). Serum CASPR2-antibodies, but not LGI1-antibodies, bound in vitro to unmyelinated human sensory neurons and rodent dorsal root ganglia, suggesting pathophysiological differences which may underlie our clinical observations. This article is protected by copyright. All rights reserved.

Original publication

DOI

10.1002/ana.26189

Type

Journal article

Journal

Ann Neurol

Publication Date

09/08/2021

Keywords

Autoantibody, Autoimmune encephalitis, CASPR2, LGI1, Pain